In phase III clinical trial of 148 patients with the International Federation of Gynecology and Obstetrics (FIGO) stage Ic–IIIc ovarian cancer, the addition of subcutaneous IFNγ treatment to the combined cisplatin and cyclophosphamide regime improved progression-free survival (PFS) to 51% in the treatment arm compared to 38% in the control group [103]. The gene discussed is IFNG; the disease is ovarian cancer.